Clobetasol propionate

Clobetasol propionate is a potent and selective CYP3A5 inhibitor with an IC50 of 0.206 μM. Clobetasol propionate has no inhibiting on CYP3A4 or other major CYPs. Clobetasol propionate is a corticosteroid and has the potential for psoriasis and other dermatoses research[1][2][3].

Product Specifications

CAS Number

[25122-46-7]

UNSPSC

12352211

Hazard Statement

H360, H373

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Clobetasol-propionate.html

Purity

99.72

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C[C@@]12[C@](C(CCl)=O)(OC(CC)=O)[C@@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O

Molecular Formula

C25H32ClFO5

Molecular Weight

466.97

Precautions

H360, H373

References & Citations

[1]William C Wright, et al. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J Med Chem. 2020 Feb 13;63 (3) :1415-1433.|[2]Steven R Feldman, et al. Topical clobetasol propionate in the treatment of psoriasis: a review of newer formulations. Am J Clin Dermatol. 2009;10 (6) :397-406.|[3]M Zeigler, et al. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with Cyclosporin A and clobetasol propionate. Lab Invest. 2001 Sep;81 (9) :1253-61.